Market closed
Pharvaris/$PHVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
Ticker
$PHVS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
83
Website
Pharvaris Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$2.52
EPS
-3.10
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
-3.1
52-week high
$33.00
52-week low
$15.00
Average daily volume
87K
Financial strength
Current ratio
18.447
Quick ratio
18.136
Long term debt to equity
0.013
Total debt to equity
0.042
Management effectiveness
Return on assets (TTM)
-26.79%
Return on equity (TTM)
-45.05%
Valuation
Price to book
3.45
Price to tangible book (TTM)
3.45
Price to free cash flow (TTM)
-9.687
Growth
Earnings per share change (TTM)
-12.76%
3-year earnings per share growth (CAGR)
0.21%
What the Analysts think about Pharvaris
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Pharvaris Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pharvaris Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pharvaris News
AllArticlesVideos
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewsWire·21 hours ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
GlobeNewsWire·4 weeks ago
Pharvaris to Host Virtual Investor Event on October 23, 2024
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pharvaris stock?
Pharvaris (PHVS) has a market cap of $1.1B as of November 13, 2024.
What is the P/E ratio for Pharvaris stock?
The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of November 13, 2024.
Does Pharvaris stock pay dividends?
No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of November 13, 2024.
When is the next Pharvaris dividend payment date?
Pharvaris (PHVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharvaris?
Pharvaris (PHVS) has a beta rating of -3.1. This means that it has an inverse relation to market volatility.